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ORIGINAL ARTICLE
Ampullary cancer is the second most common
malignancy in the periampullary region and ac-
counts for 10.2–36.0% of all surgically operable
tumors.1,2 Pancreaticoduodenectomy is the first
choice for curative resection and resection rates
range from 76.5% to 89.4%.3,4 Reported 5-year
survival rates of ampullary cancer after pancreati-
coduodenectomy range from 6.0% to 62.7% in the
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disease recurrence. Lymph node involvement was the main differentiating predictor between the late and
early recurrence groups (odds ratio, 1.982; 95% confidence interval, 1.101–3.567; p = 0.022).
Conclusion: Positive resection margin, pancreatic invasion, and lymph node involvement were found to be
predictors for disease recurrence and indicators for postoperative treatment. [J Formos Med Assoc 2007;
106(6):432–443]
Key Words: adenocarcinoma, ampulla of Vater, predictors of recurrence
©2007 Elsevier & Formosan Medical Association
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1Division of General Surgery, Department of Surgery, National Cheng Kung University Hospital, 2Institute of Clinical Medicine, College of
Medicine, National Cheng Kung University and 4Department of Surgery, Tainan Municipal Hospital, Tainan, Taiwan and 3Department of
Emergency Medicine, The Johns Hopkins University School of Medicine, Baltimore, USA.
Received: August 29, 2006
Revised: December 5, 2006
Accepted: February 6, 2007
*Correspondence to: Dr Yan-Shen Shan, Division of General Surgery, Department of Surgery, National
Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138 Sheng-Li Road,
Tainan 70428, Taiwan.
E-mail: ysshan@mail.ncku.edu.tw
Recurrence after pancreaticoduodenectomy in ampullary cancer
J Formos Med Assoc | 2007 • Vol 106 • No 6 433
literature3,5 and 35.0–62.7% in the last 10 years,
because of improvements in preoperative evalua-
tion, surgical techniques and postoperative care.6,7
However, in some patients, disease recurs and
curative resection cannot prevent distant failure.4
Recurrence rates range from 28% to 44%. Liver
metastasis, locoregional recurrence, and lymph
node recurrence are the primary modes of re-
lapse.4,8,9 Analysis of the predictors for recurrence
can establish criteria for postoperative adjuvant
therapy, which may postpone recurrence and im-
prove survival.10 Thus, in this study we collected
information regarding patients with ampullary
cancer at two high-volume hospitals using the
same operative procedures, to exclude surgery-
related factors. Various histopathologic factors
were compared between the late, early, and non-
recurrence (disease-free during follow-up) patients.
Characteristics of the relapses were analyzed and
correlation between histopathologic factors and
recurrences were evaluated, to provide a basis for
developing further therapy.
Patients and Methods
A total of 145 consecutive patients were diagnosed
with ampullary adenocarcinoma and underwent
pancreaticoduodenectomy with regional lympha-
denectomy between January 1989 and March
2006 at the National Cheng Kung University
Hospital and Tainan Municipal Hospital, both in
Tainan, Taiwan. Surgeons who performed the
operations had previously received the same,
standardized training at National Cheng Kung
University Hospital. Overall, 18 patients were ex-
cluded. Nine patients died during hospitalization
and nine patients were lost to follow-up with un-
known recurrence status. The time from opera-
tion to recurrence varied, ranging from 1 to 137
months. The median time of recurrence was 11.4
months; thus, for the purpose of data analysis, we
operationally categorized patients with recurrence
into early or late recurrence groups by the cut-
off point of 12 months. Patients without any evi-
dence of recurrence at 12 months were deemed to
belong to the non-recurrence group. Some pa-
tients who died of other causes at least 12 months
after the operation were also included in the non-
recurrence group. Age, gender, clinical presen-
tation, laboratory findings on admission and 
before operation, preoperative biliary drainage
procedures, type of resection, operative findings,
postoperative morbidity, perioperative mortality,
and histopathologic findings were recorded from
retrospective chart reviews. Percutaneous trans-
hepatic biliary drainage or endoscopic nasobiliary
drainage was used routinely to relieve obstructive
jaundice before operation if the bilirubin level
was higher than 10 mg/dL.
The type of resection, either standard or 
pylorus-preserving pancreaticoduodenectomy was
based on the surgeon’s judgment. The surgical
techniques have been described previously.11,12
During the operations, pancreatic consistency
was evaluated, subjectively, by the surgeon. The
diameters of the stumps of the pancreatic duct
and common bile duct (CBD) were measured.
Operative time, intraoperative blood loss and
units of blood transfused were recorded.
Eight patients received postoperative adju-
vant chemotherapy: six received intravenous 
fluorouracil-based chemotherapy (fluorouracil/
leucovorin + mitomycin or fluorouracil + epiru-
bicin + mitomycin) and two patients took oral
tegafur (Futraful, FT-207). Differences in disease-
free survival did not reach statistical significance
between patients with or without adjuvant therapy.
All general and procedure-related complica-
tions were taken into account. A pancreatic fistula
was determined by an amylase-rich fluid with
draining volume greater than 10mL/day, persistent
elevation of the draining amylase level and a level
three times higher than in serum for longer than
7 days.13 Operative mortality was defined as 30-day
mortality, but hospital mortality included those
who died of other associated causes in this hospi-
talization, even if occurring after more than 30 days.
Histopathology
All tumors were adenocarcinomas originating in
the ampulla of Vater. The histologic differentiation
was recorded as well, moderately, or poorly differ-
entiated. Tumor size was measured from surgical
specimens before formalin fixation. Tumor stage
and TNM stage were defined according to the
American Joint Committee on Cancer (AJCC)
classification of 2002.14
The resection margin was evaluated by the 
pathologist. R0 resection indicated that the resec-
tion margins of the pancreas, CBD, duodenum,
and retropancreatic tissue were histologically free
of carcinoma. R1 resection indicated histologi-
cally positive for carcinoma cells in the resection
margin, but grossly free, based on the surgeon’s
judgement. One patient was found to have me-
tastatic nodules over her liver surface, which was
confirmed by frozen sections during the opera-
tion. A standard pancreaticoduodenectomy was
performed without management of the liver
metastasis and she was deemed to be a case of R2
resection.
Follow-up
Follow-up at 3-month intervals comprised physical
examination, laboratory tests and tumor markers
(carcinoembryonic antigen [CEA]; cancer antigen
[CA] 125 and 199, CA-125 and CA-199). Abdo-
minal sonography was arranged every 3 months
in the first year and then every 6 months in the
second year. Computed tomography was arranged
if a positive sign was detected by abdominal
sonography or recurrence of the tumor was sus-
pected, because of, for example, elevation of a
tumor marker. Radiography of the thorax, bone
scan and computed tomography of the brain
were performed if clinical examination led to a
suspicion of metastasis.
Recurrence was categorized as locoregional or
metastatic. Disease relapse was defined as biopsy-
proven disease or radiologic evidence of recur-
rence. Local recurrence was defined as a recurrent
retroperitoneal mass or regional nodes. Metastasis
was defined as relapse of disease at a distant site,
either a visceral organ or a non-regional lymph
node. The primary end-point of the study was 
disease recurrence and the secondary end-point
was death. The primary criterion of the follow-up 
was survival time. The disease-free survival rate was
limited to the effects of ampullary cancer.
Statistical analysis
All statistical analyses were conducted using SPSS
version 12.0 (SPSS Inc., Chicago, IL, USA) for
Windows. Univariate analysis was performed using
the χ2 test or Fisher’s exact test for categorical
variables. Statistical comparisons between early,
late, and non-recurrence were conducted by one-
way ANOVA and calculated the least significant
difference between any two means for continuous
variables with normal distributions. Continuous
variables that did not follow normal distributions
were compared using the non-parametric Kruskal–
Wallis H test. Comparison between the early and
late recurrence groups was performed separately.
Categorical variables were also analyzed using the
χ2 test or Fisher’s exact test. Continuous variables
following normal distributions were compared
using Student’s independent sample t test. For
those that did not follow normal distributions, the
non-parametric Mann–Whitney U test was used.
For those factors found to be significant in the
univariate analysis with p less than 0.2, a multi-
variate analysis with the Cox proportional hazard
model was used to determine the significance of
their influence on recurrence and recurrence time.
Each model included age and gender as covariates.
The results were expressed as odds ratios (ORs)
with 95% confidence intervals (CIs) and corre-
sponding two-tailed p values. The comparison
between non-, late, and early recurrence was based
on non-recurrence as the reference group. The
comparison between late and early recurrence was
based on late recurrence as the reference group. 
p values of less than 0.05 were deemed statistically
significant.
Results
Demographic data
A total of 127 patients were enrolled; the non-
recurrence group consisted of 58 patients (46%),
the early recurrence group of 37 patients (29%)
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and the late recurrence group of 32 patients
(25%) (Table 1). There was no statistical differ-
ence between the three groups in terms of age,
gender, operative methods, operative times, blood
loss, blood transfusion, diameters of stump of pan-
creatic duct or CBD, or preoperative levels of bili-
rubin, CEA, CA-125, or CA-199. The non- and late
recurrence patients had significantly higher ratios
of soft pancreas than the early recurrence patients.
The late recurrence group had lower preoperative
albumin levels than the non- (p = 0.028) or early
recurrence groups (p = 0.006). There was no stati-
stically significant difference between the latter
two groups (p = 0.337).
Focusing on distinctions between early and late
recurrence, details of the patients’ demographic
data are shown in Table 2. The results were simi-
lar to the comparison among the three groups in
Table 1. The preoperative level of albumin was
lower in the late recurrence group and the ratio of
firm or hard pancreas was higher in early recur-
rence patients.
Histopathologic findings
There was no significant difference in tumor size,
degree of differentiation, or numbers of resected
lymph nodes among the three groups. Patients
in the early recurrence group had the highest ratio
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Table 1. Demographics, preoperative data, and operative findings in patients with ampullary cancer who underwent
pancreaticoduodenectomy: results of univariate analysis among non-, early, and late recurrence groups
Non-recurrence Late recurrence Early recurrence p
Patients, n (%) 58 (46) 32 (25) 37 (29)
Age, mean ± SD (range) 60 ± 11 (36–80) 63 ± 10 (40–83) 59 ± 11 (32–75) 0.266
Sex, n (%) 0.963
Male 33 (57) 18 (56) 20 (54)
Female 25 (43) 14 (44) 17 (46)
Total bilirubin (mg/dL), median (range)* 3.2 (0.4–16.5) 4.6 (0.4–26.4) 3.9 (0.2–19.6) 0.379
Direct bilirubin (mg/dL), median (range)* 1.6 (0–9.1) 3.3 (0–25.2) 3.4 (0.1–18.0) 0.083
Albumin (mg/dL), median (range)* 3.5 (2.5–4.8) 3.3 (2.5–4.2) 3.6 (2.8–4.8) 0.017
Operative methods, n (%) 0.063
Whipple 27 (47) 23 (72) 21 (57)
Pancreaticoduodenectomy 31 (53) 9 (28) 16 (43)
Operative time (min), median (range)* 235 (150–765) 255 (197–680) 286 (180–735) 0.053
Blood loss (mL), median (range)* 465 (100–1800) 500 (150–2360) 600 (150–2700) 0.277
Blood transfusion (units), median (range)* 0 (0–6) 0 (0–8) 2 (0–6) 0.219
Stump of pancreatic duct (mm), median (range)* 2 (1–10) 3 (1–10) 3 (1–8) 0.129
Stump of common bile duct (mm), median (range)* 14 (2–25) 19 (6–27) 14 (7–25) 0.128
Consistency of pancreas*, n (%) 0.020
Soft 24 (83) 12 (92) 9 (50)
Firm 3 (10) 0 7 (39)
Hard 2 (7) 1 (8) 2 (11)
CEA (U/dL), median (range)* 1.6 (0.1–13.0) 1.3 (0.1–296.3) 1.7 (0.6–41.4) 0.539
CA-125 (U/dL), median (range)* 12.8 (2.7–36.0) 17.8 (0.5–164.1) 18.3 (5.4–65.7) 0.170
CA-199 (U/dL), median (range)* 55 (0–1860) 38 (2–7513) 88 (2–2329) 0.404
*Excluding missing data. SD = standard deviation; CEA = carcinoembryonic antigen; CA = cancer antigen.
of pancreatic invasion, advanced tumor stage,
lymph node involvement, advanced tumor and
AJCC TNM stage (Table 3). All patients in the non-
and late recurrence groups had complete resection
(R0 resection), while six patients in the early re-
currence group had residual microscopic disease 
(R1 resection) and one patient had grossly evident
residual liver metastasis (R2 resection). Regarding
tumor stage, no patient in the early recurrence
group had a T1 lesion, 27% had T2 lesions and
73% had T3 or T4 lesions, while only 39% in the
late and 26% in the non-recurrence groups had
T3 or T4 lesions. The ratio of lymph node in-
volvement was 72% in the early, 47% in the late
and 18% in the non-recurrence groups. The non-
recurrence patients had earlier stage disease (63%
in stage I, 30% in stage II, 7% in stage III), while the
early recurrence patients had the most advanced
disease (5% in stage I, 65% in stage II, 27% in
stage III, 3% in stage IV) (Table 3). There was no
difference in the number of total dissected lymph
nodes among the three groups, or between pa-
tients with and without lymph node involvement.
There was also no correlation between the num-
ber of dissected/positive lymph nodes and tumor
size (data not shown). The univariate analysis of
risk factors between early and late recurrence is
described separately (Table 4). Pancreatic invasion,
H.P. Hsu, et al
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Table 2. Demographics, preoperative data, and operative findings in patients with ampullary cancer who
underwent pancreaticoduodenectomy: results of univariate analysis between early and late
recurrence groups
Late recurrence Early recurrence p
Patients, n (%) 32 (46) 37 (54)
Age, mean ± SD (range) 63 ± 10 (40–83) 59 ± 11 (32–75) 0.469
Sex, n (%) 1.000
Male 18 (56) 20 (54)
Female 14 (44) 17 (46)
Total bilirubin (mg/dL), median (range)* 4.6 (0.4–26.4) 3.9 (0.2–19.6) 0.705
Direct bilirubin (mg/dL), median (range)* 3.3 (0–25.2) 3.4 (0.1–18.0) 0.670
Albumin (mg/dL), median (range)* 3.3 (2.5–4.2) 3.6 (2.8–4.8) 0.019
Operative methods, n (%) 0.219
Whipple 23 (72) 21 (57)
Pancreaticoduodenectomy 9 (28) 16 (43)
Operative time (min), median (range)* 255 (197–680) 286 (180–735) 0.334
Blood loss (mL), median (range)* 500 (150–2360) 600 (150–2700) 0.953
Blood transfusion (units), median (range)* 0 (0–8) 2 (0–6) 0.590
Stump of pancreatic duct (mm), median (range)* 3 (1–10) 3 (1–8) 0.993
Stump of common bile duct (mm), median (range)* 19 (6–27) 14 (7–25) 0.148
Consistency of pancreas*, n (%) 0.028
Soft 12 (92) 9 (50)
Firm 0 7 (39)
Hard 1 (8) 2 (11)
CEA (U/dL), median (range)* 1.3 (0.1–296.3) 1.7 (0.6–41.4) 0.542
CA-125 (U/dL), median (range)* 17.8 (0.5–164.1) 18.3 (5.4–65.7) 0.780
CA-199 (U/dL), median (range)* 38 (2–7513) 88 (2–2329) 0.471
*Excluding missing data. SD = standard deviation; CEA = carcinoembryonic antigen; CA = cancer antigen.
tumor stage, resection, numbers of positive lymph
node, lymph node involvement, and AJCC TNM
stage were poor predictors.
A total of 26 patients (72%) in the early recur-
rence group had pancreatic invasion, compared
with 11 patients (36%) in the late and 15 patients
(26%) in the non-recurrence groups (Table 3).
Furthermore, the ratios of moderate and poor dif-
ferentiation were higher in tumors with pancreatic
invasion (51% and 16% separately in tumors with
pancreatic invasion, compared with 35% and 7%
in those without; p = 0.023). The patients with
pancreatic invasion also had greater lymph node
involvement (58% in those with and 28% in
those without pancreatic invasion) and numbers
of positive lymph nodes (median, 1 lymph node
in those with pancreatic invasion, compared with
zero in those without). However, tumor size did
not show a significant relationship with pancreatic
invasion (Table 5).
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Table 3. Histopathologic findings in patients with ampullary cancer who underwent pancreaticoduodenectomy:
results of univariate analysis among non-, early, and late recurrence groups
Non-recurrence Late recurrence Early recurrence p
Patients, n (%) 58 (46) 32 (25) 37 (29)
Tumor size (cm), median (range) 1.8 (0.5–7.0) 2.0 (0.7–6.5) 2.0 (1.0–8.0) 0.101
Pancreatic invasion*, n (%) < 0.001
Negative 42 (74) 20 (65) 10 (28)
Positive 15 (26) 11 (36) 26 (72)
Tumor stage*, n (%) < 0.001
T1 11 (19) 2 (7) 0
T2 31 (54) 17 (55) 10 (27)
T3 11 (19) 8 (26) 17 (46)
T4 4 (7) 4 (13) 10 (27)
Resection margin, n (%) 0.001
R0 57 (100) 31 (100) 29 (81)
R1 0 0 6 (17)
R2 0 0 1 (3)
Resected lymph node (n), 7 (0–37) 9 (2–40) 10 (1–24) 0.279
median (range)
Positive lymph node (n), 0 (0–8) 0 (0–9) 2 (0–9) < 0.001
median (range)
Lymph node status*, n (%) < 0.001
Negative 47 (83) 17 (53) 10 (28)
Positive 10 (18) 15 (47) 26 (72)
Differentiation*, n (%) 0.127
Well 29 (55) 16 (53) 11 (31)
Moderate 20 (38) 12 (40) 18 (50)
Poor 4 (8) 2 (7) 7 (19)
AJCC TNM stage*, n (%) < 0.001
Stage I 36 (63) 13 (42) 2 (5)
Stage II 17 (30) 14 (45) 24 (65)
Stage III 4 (7) 4 (13) 10 (27)
Stage IV† 0 0 1 (3)
*Excluding missing data; †residual liver metastases. AJCC = American Joint Committee on Cancer.
Recurrence patterns and follow-up
All patients in the non-recurrence group had no
recurrent disease at follow-up. The patterns of re-
lapse in the early and late recurrence groups as
shown in Table 6 included 38 liver metastases, 34
locoregional recurrences, 13 peritoneal carcino-
matoses, 9 bone metastases, and 18 other sites,
including brain, lung, ovarian, mesocolon and
para-aortic lymph node metastases (34 patients
had more than one site of metastasis). The recur-
rence patterns were similar between the early and
late recurrence groups. In our previous study, lymph
node involvement was a significant predictor for
liver metastasis in a multivariate analysis and pan-
creatic invasion was a predictor for locoregional
recurrence.15
We further compared risk factors among the
three groups in this study. In a univariate analysis,
preoperative albumin data, pancreatic invasion,
tumor stage, lymph node involvement, positive
resection margin and AJCC TNM stage were sig-
nificant predictors (Tables 1 and 3). Only positive
resection margin (OR, 2.929; 95% CI, 1.137–
7.542; p = 0.026), pancreatic invasion (OR, 3.562;
95% CI, 1.953–6.495; p < 0.001) and lymph node
involvement (OR, 2.767; 95% CI, 1.516–5.052;
H.P. Hsu, et al
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Table 4. Histopathologic findings in patients with ampullary cancer who underwent pancreaticoduodenectomy:
results of univariate analysis between early and late recurrence groups
Late recurrence Early recurrence p
Patients, n (%) 32 (46) 37 (54)
Tumor size (cm), median (range) 2.0 (0.7–6.5) 2.0 (1.0–8.0) 0.969
Pancreatic invasion*, n (%) 0.003
Negative 20 (65) 10 (28)
Positive 11 (36) 26 (72)
Tumor stage*, n (%) 0.027
T1 2 (7) 0
T2 17 (55) 10 (27)
T3 8 (26) 17 (46)
T4 4 (13) 10 (27)
Resection margin*, n (%) 0.035
R0 31 (100) 29 (81)
R1 0 6 (17)
R2 0 1 (3)
Resected lymph node (n), median (range) 9 (2–40) 10 (1–24) 0.469
Positive lymph node (n), median (range) 0 (0–9) 2 (0–9) 0.058
Lymph node status*, n (%) 0.047
Negative 17 (53) 10 (28)
Positive 15 (47) 26 (72)
Differentiation*, n (%) 0.111
Well 16 (53) 11 (31)
Moderate 12 (40) 18 (50)
Poor 2 (7) 7 (19)
AJCC TNM stage*, n (%) 0.003
Stage I 13 (42) 2 (5)
Stage II 14 (45) 24 (65)
Stage III 4 (13) 10 (27)
Stage IV† 0 1 (3)
*Excluding missing data; †residual liver metastases.
p=0.001) were significant in the multivariate analy-
sis, with the non-recurrence group as the reference
group (Table 7). If we focused on the contrast 
between early and late recurrence, only lymph
node involvement was a predictor of recurrence
(OR, 1.982; 95% CI, 1.101–3.567; p = 0.022).
Non-free resection margin and pancreatic inva-
sion did not reach statistical significance in the
multivariate analysis (Table 8).
The median follow-up in the non-recurrence
group was 65 months (range, 12–205 months). The
median survival time (from operation to death)
in the late recurrence group was 36 months (range,
16–137 months). The median time from surgery
to recurrence in the late recurrence group was 24
months (range, 13–137 months) and the median
time from disease recurrence to death was 4
months (range, 0–29 months). The median sur-
vival time (from operation to death) in the early
recurrence group was 13 months (range, 3–63
months). The median time from surgery to recur-
rence in the early recurrence group was 5 months
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Table 5. Correlation between pancreatic invasion and other histopathologic factors in patients with ampullary
cancer who underwent pancreaticoduodenectomy: results of univariate analysis
Pancreatic invasion
p
Negative Positive
Patients, n (%)* 72 (58) 52 (42)
Tumor size (cm), median (range)* 2.0 (0.5–7.0) 2.0 (0.7–8.0) 0.122
Resection margin*, n (%) 0.003
R0 71 (99) 46 (89)
R1 0 6 (12)
R2 1 (1)† 0
Lymph node status*, n (%) 0.001
Negative 52 (72) 22 (42)
Positive 20 (28) 30 (58)
Total dissected lymph nodes, median (range)* 9 (1–40) 8 (0–18) 0.700
Positive lymph nodes, median (range)* 0 (0–9) 1 (0–9) 0.001
Differentiation*, n (%) 0.027
Well 39 (57) 17 (33)
Moderate 24 (35) 26 (51)
Poor 5 (7) 8 (16)
*Excluding missing data; †residual liver metastases.
Table 6. Recurrence patterns in 69 patients with ampullary cancer who underwent pancreaticoduodenectomy,
comparing early and late recurrence groups
Late recurrence, n (%) Early recurrence, n (%) p
Liver metastasis 15 (47) 23 (62) 0.232
Local recurrence 16 (50) 18 (49) 1.000
Peritoneal carcinomatosis 5 (16) 8 (22) 0.556
Bone metastasis 6 (19) 3 (8) 0.285
Other metastases* 9 (28) 10 (27) 1.000
Total 32 37
*Including brain, lung, ovarian, mesocolon and para-aortic lymph nodes metastases.
(range, 0–12 months) and the median time from
disease recurrence to death was 6 months (range, 0–
29 months). Three patients in the late recurrence
and four in the early recurrence groups died of dis-
eases other than ampullary cancer. Four patients
in the late and two in the early recurrence groups
received adjuvant chemotherapy. Three patients in
the late and two in the early recurrence groups were
still receiving salvage chemotherapy after recurrence.
Most received gemcitabine-based regimens (six
of seven patients). One patient developed stable
disease 6 months after FOLFOX chemotherapy (5-
fluorouracil + leucovorin + oxaliplatin, bi-weekly).
One patient received salvage chemoradiotherapy
(gemcitabine+oxaliplatin+5-fluorouracil, followed
by oral tegafur + uracil, UFUR) for liver and bone
metastases and follow-up with disease at 24
months. The survival rates between patients re-
ceiving adjuvant or salvage chemoradiotherapy
or not were not statistically significantly different
(data not shown).
Discussion
Carcinoma of the ampulla of Vater is a rare neo-
plasm, but has a relatively favorable prognosis
compared with other periampullary neoplasms,
such as those of the pancreatic head or distal bile
duct.3,16 In recent reports, the 5-year disease-free
H.P. Hsu, et al
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Table 8. Multivariate analysis of predictors for recurrence in patients with ampullary cancer who underwent
pancreaticoduodenectomy, comparing the early and late recurrence groups, with late recurrence as
the reference group
OR 95% CI p
Resection margin 0.335
R1 or R2 1.502 0.657–3.435
R0 1
Pancreatic invasion 0.162
Positive 1.501 0.849–2.655
Negative 1
Lymph node status 0.022
Positive 1.982 1.101–3.567
Negative 1
OR = odds ratio; CI = confidence interval.
Table 7. Multivariate analysis of predictors for recurrence in patients with ampullary cancer who underwent
pancreaticoduodenectomy, comparing the non-, early, and late recurrence groups, with the 
non-recurrence group as the reference group
OR 95% CI p
Resection margin 0.026
R1 or R2 2.929 1.137–7.542
R0 1
Pancreatic invasion < 0.001
Positive 3.562 1.953–6.495
Negative 1
Lymph node status 0.001
Positive 2.767 1.516–5.052
Negative 1
OR = odds ratio; CI = confidence interval.
survival rate was 35.0–62.7%, thus making ade-
nocarcinoma of the ampulla of Vater the most
curable of the carcinomas of the upper gastro-
intestinal tract.6,7 In our previous study, 135 pa-
tients with ampullary adenocarcinoma underwent
pancreaticoduodenectomy in the years 1989–2005.
Operative mortality was 3% and the 5-year sur-
vival rate was 45.7%.15 In this study, a compara-
tive study between 37 early recurrence patients,
32 late recurrence patients, and 58 non-recurrence
patients after curative resection for ampullary
cancer was performed. Recurrence was associated
with preoperative albumin data, pancreatic in-
vasion, tumor stage, lymph node involvement,
non-free resection margin, and AJCC TNM stage.
Only lymph node involvement was a significant
predictor for recurrence within the postoperative
12 months.
In the literature, several risk factors for am-
pullary cancer have been identified, including
tumor size, histologic grade, invasion depth, tumor
morphology, lymph node involvement, blood trans-
fusion and positive resection margin.1,4–9 The most
common pattern of failure in ampullary cancer is
liver metastasis, ranging from 53% to 67%, followed
by distant lymph nodes (28–60%), peritoneal car-
cinomatosis (20–21%), and lung (21–22%) and
bone metastasis (13–17%). The incidence of loco-
regional recurrence is variable, from 33% to 60%,
but is usually combined with distant metastasis
(50–100%).4,8,9 In the present study, a total of 69
patients (54%) developed disease relapse and 34
patients had more than one site of metastasis.
Thirty-eight patients (55%) suffered liver metas-
tasis, though only 13 patients (19%) had liver me-
tastasis alone. Locoregional recurrence was noted
in 34 patients (49%), while 16 patients (23%) had
pure locoregional disease. Other sites of metastases
included 13 cases of peritoneal carcinomatosis,
10 distant lymph nodes, 9 bone, 6 lung, 2 meso-
colon, 1 brain, and 1 ovary. The patterns of recur-
rence were similar in the early and late recurrence
groups. In our follow-up protocol, regular exam-
inations included blood sampling and abdomi-
nal sonography every 3 months in the first year,
then every 6 months in the second year. Computed
tomography, radiography of the thorax, bone scan
and computed tomography of the brain were read-
ily available if there was any clinical suspicion of
metastasis. Focusing on predictors for recurrence
and the relationship with time can further identify
high-risk patients and help in making decisions
regarding postoperative therapy.
Lymph node involvement is a significant pre-
dictor for poor prognosis.2,4,6,7,15–22 In a Memorial
Sloan-Kettering Cancer Center report, the median
survival time in patients with lymph node involve-
ment was only 23.6 months, while it was 69.7
months in patients without lymph node involve-
ment.17 The 5-year survival rate was only 0–30%
in patients with lymph node involvement, but
39–78% in patients without lymph node involve-
ment in the literature.4,7,16,18–22 Klempnauer et al23
identified determinants of long-term survival after
resection of ampullary cancer by comparison of
short and long survivors. They found that tumor
size, lymph node metastases, UICC (International
Union Against Cancer) stage and grading had 
a significant impact on long survival, but only
tumor size had independent prognostic signifi-
cance in a multivariate analysis. They presumed
that the patients with advanced tumor size also
had a higher proportion of positive lymph nodes.
However, in our study, lymph node involvement
was a significant predictor for recurrence in both
the univariate and multivariate analyses. We ana-
lyzed tumor size between patients with or without
lymph node involvement and found that there
was no significant difference (p = 0.089). Further
comparisons among the three groups showed that
the effect of lymph node involvement was signif-
icant between any two groups. Thus, we believe
that lymph node involvement is a major predic-
tor for distant failure and disease recurrence in
patients with ampullary cancer. Lymph node in-
volvement may indicate more advanced disease
characteristics and, perhaps, microscopic tumor
seeding before surgery.
In addition to lymph node status, microscopic
lymphatic duct and lymphovascular invasion are
also significant predictors.4,18,21 Böttger et al7 re-
ported that the ratio of metastatic to dissected
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lymph nodes is an independent predictor. In re-
cent studies, modern techniques to detect lymph
node micrometastasis, for example, by immuno-
histochemistry with anti-cytokeratin monoclonal
antibodies, can identify the highest risk patients
with lymph node metastases, with greatly im-
proved sensitivity over conventional hematoxy-
lin and eosin staining.24,25 In the present study,
there was no difference in the number of dissected
lymph nodes among the three groups. However,
the number of positive lymph nodes by conven-
tional hematoxylin and eosin staining does corre-
late with long-term survival and timing of disease
relapse.
Large tumor size may be associated with depth
of invasion, which contributes to the impact on
lymph node metastases and disease recurrence.
Beger et al19 reviewed 126 patients with ampullary
carcinomas and concluded that pancreatic inva-
sion indirectly indicated the status of regional
lymph node metastases and prognosis. Shirai 
et al26 focused on a histopathologic analysis of
tumor spreading in pancreaticoduodenectomy spec-
imens. Once the tumors penetrate the sphincter
of Oddi, ampullary cancer causes nodal involve-
ment and recurrences. The depth of invasion is a
significant parameter of both the degree of tumor
spreading and prognosis. In a recent study by
Yoon et al,16 intraoperative transfusion, depth of
invasion, lymph node metastasis, differentiation,
and lymphovascular invasion were independent,
significant prognostic factors in a multivariate ana-
lysis, but tumor size was not. In our study, tumor
size did not correlate with the depth of invasion,
and patients with pancreatic invasion had higher
levels of lymph node involvement. In the multivari-
ate analysis, pancreatic invasion was a significant
predictor for disease relapse, with non-recurrence
as the reference group, but tumor size was not.
Comparing the early and late recurrence groups,
the effect of pancreatic invasion was eliminated by
lymph node involvement in a multivariate analy-
sis. Based on the anatomic distribution of vessels
and lymph nodes, we believe that pancreatic 
invasion may cause a higher incidence of node
involvement and then distant metastasis. If the
tumor grows into the duodenal lumen, but not
into the pancreas, large tumor size is not neces-
sary to cause subsequent metastasis. Thus, a nega-
tive effect on disease recurrence would be expected
from pancreatic invasion and subsequent lymph
node involvement, not large tumor size.
Negative resection margin is an independent
predictor favoring long-term survival in periam-
pullary adenocarcinomas. Patients with ampullary
adenocarcinoma have a significantly lower inci-
dence of positive resection margins (range, 3–9%).2
Patients with R0 resections have better prognoses
than those with R1 resections.17,19 However, the
significance of resection was lost on multivariate
analysis, comparing with serum bilirubin level,
blood loss, operation type, diagnosis and lymph
node status.16 In the present study, all patients 
in the non-recurrence and late recurrence groups
had R0 resections. Six patients with R1 resections
and one patient with R2 resection developed re-
current disease within 12 months. All died after
salvage chemoradiotherapy. Positive resection mar-
gin was one of the worst predictors, not only in
univariate but also in multivariate analyses. In all
patients with ampullary adenocarcinoma, careful
preoperative assessment and complete operative
resection is important. In patients with positive
surgical margins or other unfavorable features
(such as lymph node involvement, pancreatic inva-
sion or poorly differentiated tumor grade), adju-
vant chemoradiotherapy is indicated.10 However,
in studies by Sikora et al,27 a total of 113 patients
underwent pancreaticoduodenectomy, and adju-
vant chemoradiotherapy was administered to 59
high-risk patients. There was apparently no ben-
efit in long-term survival or decreased recurrence
rates. In such high-risk patients (positive resec-
tion margin, pancreatic invasion, and/or lymph
node involvement), we strongly recommend that
new postoperative adjuvant therapy is developed
to improve survival.
In conclusion, positive resection margin, lymph
node status and pancreatic invasion are significant
predictors for disease recurrence in patients with
ampullary cancer. Liver metastases and locoregio-
nal recurrence are the main types of relapse. There
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is currently no accepted regimen for postoperative
adjuvant therapy and we suggest further research
on pre- and postoperative adjuvant therapy to
improve survival in these high-risk patients.
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